CYP19A1 and breast cancer: In premenopausal women, the drug of choice was Tamoxifen for at least 5 years, with associated ovary function suppression (OFS) [6], while latest evidence indicates that using an aromatase inhibitor rather than tamoxifen with OFS, reduces the risk of breast cancer recurrence [7].